RxDoctor Payments Data

Anh Vu, MD

Cardiovascular Disease · Fredricksburg, VANPI 1023050010

Payments from drug & device makers

$1,942in general payments, 2019–2025

Across 59 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$422
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
  • Abbott$183
  • Amgen$165
  • Medtronic$164
  • Akcea Therapeutics, Inc.$126
  • plus $677 from 21 others

What the payments were for

  • Food & beverage$1,942100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,942 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$1,212,962
Medicare patients
2,684
Services billed
9,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$260,859
XareltoRivaroxaban52$67,469
EntrestoSacubitril/Valsartan12$19,768
Repatha SureclickEvolocumab15$11,244
Atorvastatin Calcium529$4,804
Metoprolol Succinate247$3,541
Carvedilol457$3,513
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine15$3,037
ClopidogrelClopidogrel Bisulfate207$2,800
Rosuvastatin Calcium166$2,780
Prasugrel Hcl11$2,428
Ezetimibe50$2,102
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$2,034
Labetalol Hcl41$1,998
Amlodipine Besylate300$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$260,859211 claims
Johnson & JohnsonXarelto$47$67,46952 claims
NovartisEntresto$52$19,76812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Fredricksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →